Greenleaf Health is a leading FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies researching, developing, and manufacturing innovative solutions to pressing global public health challenges.
Greenleaf has expanded its portfolio of services to include comprehensive on-site compliance assessments, remediation and inspection readiness.
Greenleaf’s expansion includes additional technical experts who can be deployed to support the firm’s robust strategic and technical expertise.
Learn MoreWASHINGTON, D.C. – Greenleaf Health, a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces that the firm has expanded its compliance and manufacturing portfolio to include Good …
Read More
WASHINGTON, D.C, October 1, 2019— Greenleaf Health, a leading Food and Drug Administration (FDA) regulatory consulting firm, today announced it has entered into an exclusive agreement with Trio Health, a …
Read More
Karen Midthun, M.D. & John Taylor to Lead Team of Experts WASHINGTON, D.C. – Greenleaf Health, Inc., a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces that …
Read More
Firm Announces Dr. Midthun as Principal, Drug and Biological Products WASHINGTON, D.C. – Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA or agency) regulatory consulting firm, today …
Read More
Greenleaf Health announces that Kristen Grumet has joined the firm as Senior Vice President, Regulatory Compliance. The addition of Grumet to Greenleaf’s team of experts further enhances the firm’s expanded …
Read More
Greenleaf Health today announced the firm has expanded its portfolio of services to include comprehensive on-site compliance assessments, remediation, and inspection readiness. By expanding Greenleaf’s compliance service portfolio, the firm …
Read More
Greenleaf Health announces that Robert (Bob) Meyer, M.D. has joined the firm as Principal, Drug and Biological Products. Dr. Meyer and Dr. John Jenkins, Principal, Drug and Biological Products, will …
Read More
